このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Amphastar Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Amphastar Pharmaceuticals'の CEO はJack Zhangで、 Jan1996年に任命され、 の在任期間は 28.42年です。 の年間総報酬は$ 7.72Mで、 11.6%給与と88.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の4.78%を直接所有しており、その価値は$ 94.99M 。経営陣と取締役会の平均在任期間はそれぞれ10.6年と5年です。
主要情報
Jack Zhang
最高経営責任者
US$7.7m
報酬総額
| CEO給与比率 | 11.6% |
| CEO在任期間 | 28.4yrs |
| CEOの所有権 | 4.8% |
| 経営陣の平均在職期間 | 10.6yrs |
| 取締役会の平均在任期間 | 5yrs |
経営陣の近況
Recent updates
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13Amphastar Pharma: A Well-Run, Diversified Mid Cap
Jan 26CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
報酬と市場: Jackの 総報酬 ($USD 7.72M ) は、 US市場 ($USD 5.64M ) の同規模の企業の平均を上回っています。
報酬と収益: Jackの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Jack Zhang (77 yo)
28.4yrs
在職期間
US$7,722,768
報酬
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman of the Board | 28.4yrs | US$3.77m | 2.34% $ 46.4m | |
| Co-founder | 28.4yrs | US$7.72m | 4.78% $ 94.7m | |
| CFO, Executive VP of Finance | 10.2yrs | US$2.89m | 0.081% $ 1.6m | |
| Executive VP of Sales | 11yrs | US$1.78m | 0.095% $ 1.9m | |
| Senior EVP of Production & EVP of Scientific Affairs | 9yrs | US$2.03m | 0.38% $ 7.6m | |
| Senior Vice President of Human Resources & Corporate Communication | 1.8yrs | データなし | データなし | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | データなし | データなし |
10.6yrs
平均在職期間
65yo
平均年齢
経験豊富な経営陣: AMPHの経営陣は経験豊富で経験豊富です（平均在職期間は10.6年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman of the Board | 28.4yrs | US$3.77m | 2.34% $ 46.4m | |
| Co-founder | 28.4yrs | US$7.72m | 4.78% $ 94.7m | |
| CFO, Executive VP of Finance | 1.8yrs | US$2.89m | 0.081% $ 1.6m | |
| Executive VP of Sales | 1.8yrs | US$1.78m | 0.095% $ 1.9m | |
| Lead Independent Director | 22.3yrs | US$362.00k | 0.058% $ 1.1m | |
| Independent Director | 3yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5yrs | US$314.70k | 0.026% $ 520.0k |
5.0yrs
平均在職期間
65.5yo
平均年齢
経験豊富なボード: AMPHの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。